Skip to main content
Top
Published in: BMC Immunology 1/2015

Open Access 01-12-2015 | Research article

Increased levels of interleukin 31 (IL-31) in osteoporosis

Authors: Lia Ginaldi, Massimo De Martinis, Fedra Ciccarelli, Salvatore Saitta, Selene Imbesi, Carmen Mannucci, Sebastiano Gangemi

Published in: BMC Immunology | Issue 1/2015

Login to get access

Abstract

Background

Several inflammatory cytokines play a key part in the induction of osteoporosis. Until now, involvement of the Th2 cytokine interleukin-31 (IL-31) in osteoporosis hadn’t yet been studied. IL-31 is a proinflammatory cytokine mediating multiple immune functions, whose involvement in a wide range of diseases, such as atopic dermatitis, inflammatory bowel diseases and cutaneous lymphomas, is now emerging. Given the important role of IL-31 in inflammation, we measured its serum levels in postmenopausal osteoporotic patients.

Methods and results

In fifty-six postmenopausal females with osteoporosis and 26 healthy controls, bone mineral density (BMD) measurements were performed by using calcaneal quantitative ultrasound (QUS) technique, confirmed at the lumbar spine and hip by dual energy X-ray absorptiometry (DXA). Both patients and controls were divided according to age (less or more than 65 years) and disease severity (T-score levels and presence of fractures). Serum IL-31 levels were measured by ELISA technique. Osteoporotic patients exhibited elevated levels of serum IL-31 compared with healthy controls (43.12 ± 6.97 vs 29.58 ± 6.09 pg/ml; p < 0.049). IL-31 expression was higher in over 65 years old patients compared to age-matched controls (45 ± 11.05 vs. 17.92 ± 5.92; p < 0.01), whereas in younger subjects no statistically significant differences were detected between patients and controls (37.91 ± 6.9 vs 32.08 ± 8.2). No statistically significant differences were found between IL-31 levels in patients affected by mild (T-score > -3) compared to severe (T-score < -3) osteoporosis (59.17 ± 9.22 vs 37.91 ± 10.52), neither between fractured and unfractured osteoporotic women (33.75 ± 9.16 vs 51.25 ± 8.9).

Conclusions

We showed for the first time an increase of IL-31 serum levels in postmenopausal women with decreased BMD. Although they did not reflect the severity of osteoporosis and/or the presence of fractures, they clearly correlated with age, as reflected by the higher levels of this cytokine in aged patients.
Literature
1.
go back to reference Rauner M, Sipos W, Thiele S, Pietschmann P. Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities. Int Arch Allergy Immunol. 2013;160:114–25.CrossRefPubMed Rauner M, Sipos W, Thiele S, Pietschmann P. Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities. Int Arch Allergy Immunol. 2013;160:114–25.CrossRefPubMed
3.
go back to reference Zupan J, Jeras M, Marc J. Osteoimmunology and the influence of proinflammatory cytokines on osteoclasts. Biochem Med. 2013;23:43–63.CrossRef Zupan J, Jeras M, Marc J. Osteoimmunology and the influence of proinflammatory cytokines on osteoclasts. Biochem Med. 2013;23:43–63.CrossRef
4.
go back to reference Deal C. Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep. 2012;14:231–7.CrossRefPubMed Deal C. Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep. 2012;14:231–7.CrossRefPubMed
5.
go back to reference Sigl V, Penninger JM: RANKL/RANK-From bone physiology to breast cancer. Cytokine Growth Factor Rev 2014. doi: 10.1016/j.cytogfr.2014.01.002 Sigl V, Penninger JM: RANKL/RANK-From bone physiology to breast cancer. Cytokine Growth Factor Rev 2014. doi: 10.1016/j.cytogfr.2014.01.002
6.
go back to reference Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract. 2006;12:436–45.CrossRefPubMed Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract. 2006;12:436–45.CrossRefPubMed
7.
go back to reference De Martinis M, Di Benedetto MC, Mengoli LP, Ginaldi L. Senile osteoporosis: is it an immune-mediated disease? Inflamm Res. 2006;55:399–404.CrossRefPubMed De Martinis M, Di Benedetto MC, Mengoli LP, Ginaldi L. Senile osteoporosis: is it an immune-mediated disease? Inflamm Res. 2006;55:399–404.CrossRefPubMed
9.
10.
11.
go back to reference Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM, Tuck SP. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol. 2011;64:354–7.CrossRefPubMed Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM, Tuck SP. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol. 2011;64:354–7.CrossRefPubMed
12.
go back to reference Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci. 2007;1116:360–75.CrossRefPubMed Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci. 2007;1116:360–75.CrossRefPubMed
13.
15.
go back to reference Fujii T, Kitaura H, Kimura K, Hakami ZW, Takano-Yamamoto T. IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo. Bone. 2012;51:771–80.CrossRefPubMed Fujii T, Kitaura H, Kimura K, Hakami ZW, Takano-Yamamoto T. IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo. Bone. 2012;51:771–80.CrossRefPubMed
16.
go back to reference Saleh H, Eeles D, Hodge JM, Nicholson GC, Gu R, Pompolo S, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology. 2011;152:1911–22.CrossRefPubMed Saleh H, Eeles D, Hodge JM, Nicholson GC, Gu R, Pompolo S, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology. 2011;152:1911–22.CrossRefPubMed
17.
go back to reference Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19:347–56.PubMedCentralCrossRefPubMed Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19:347–56.PubMedCentralCrossRefPubMed
18.
go back to reference Cheung PF, Wong CK, Ho AW, Hu S, Chen DP, Lam CW. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010;22:453–67.CrossRefPubMed Cheung PF, Wong CK, Ho AW, Hu S, Chen DP, Lam CW. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010;22:453–67.CrossRefPubMed
19.
go back to reference Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, et al. IL-31 a cytokine involved in immunity and inflammation. Int J Immunopathol Pharmacol. 2010;23:709–13.PubMed Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, et al. IL-31 a cytokine involved in immunity and inflammation. Int J Immunopathol Pharmacol. 2010;23:709–13.PubMed
20.
go back to reference Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752–60.CrossRefPubMed Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752–60.CrossRefPubMed
21.
go back to reference Broxmeyer HE, Li J, Hangoc G, Cooper S, Tao W, Mantel C, et al. Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31. Exp Hematol. 2007;35:78–86.PubMedCentralCrossRefPubMed Broxmeyer HE, Li J, Hangoc G, Cooper S, Tao W, Mantel C, et al. Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31. Exp Hematol. 2007;35:78–86.PubMedCentralCrossRefPubMed
22.
go back to reference Stott B, Lavender P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CBJ. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. Allergy Clin Immunol. 2013;32:446–54.CrossRef Stott B, Lavender P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CBJ. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. Allergy Clin Immunol. 2013;32:446–54.CrossRef
23.
go back to reference Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411–7.CrossRefPubMed Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411–7.CrossRefPubMed
24.
go back to reference Bando T, Morikawa Y, Komori T, Senba E. Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns. Neuroscience. 2006;142:1263–71.CrossRefPubMed Bando T, Morikawa Y, Komori T, Senba E. Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns. Neuroscience. 2006;142:1263–71.CrossRefPubMed
25.
go back to reference Cevikbas F, Wang X, Akiyama T, Kempkes C, Terhi Savinko T, Antal A, et al. A Sensory neuron-expressed interleukin-31 receptor mediates t helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448–60.PubMedCentralCrossRefPubMed Cevikbas F, Wang X, Akiyama T, Kempkes C, Terhi Savinko T, Antal A, et al. A Sensory neuron-expressed interleukin-31 receptor mediates t helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448–60.PubMedCentralCrossRefPubMed
26.
go back to reference Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy. 2010;65:712–21.CrossRefPubMed Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy. 2010;65:712–21.CrossRefPubMed
27.
go back to reference Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006;118:930–7.CrossRefPubMed Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006;118:930–7.CrossRefPubMed
28.
go back to reference Nobbe S, Dziunycz P, Mühleisen B, Bilsborough J, Dillon SR, French LE, et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol. 2012;92:24–8.CrossRefPubMed Nobbe S, Dziunycz P, Mühleisen B, Bilsborough J, Dillon SR, French LE, et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol. 2012;92:24–8.CrossRefPubMed
29.
go back to reference Dambacher J, Beigel F, Seiderer J, Haller D, Goke B, Auernhammer CJ, et al. Interleukin-31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut. 2007;56:1257–65.PubMedCentralCrossRefPubMed Dambacher J, Beigel F, Seiderer J, Haller D, Goke B, Auernhammer CJ, et al. Interleukin-31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut. 2007;56:1257–65.PubMedCentralCrossRefPubMed
30.
go back to reference Lee CH, Hong CH, Yu WT, Chuang HY, Huang SK, Chen GS, et al. Mechanistic correlations between two hitch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3/calcium axis in atopic dermatitis. Br J Dermatol. 2012;167:794–803.PubMedCentralCrossRefPubMed Lee CH, Hong CH, Yu WT, Chuang HY, Huang SK, Chen GS, et al. Mechanistic correlations between two hitch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3/calcium axis in atopic dermatitis. Br J Dermatol. 2012;167:794–803.PubMedCentralCrossRefPubMed
31.
go back to reference Wong CK, Leung KM, Qiu HN, Chow JY, Choi AO, Lam CW: Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One. 2012, doi:10.1371/journal.pone.0029815 Wong CK, Leung KM, Qiu HN, Chow JY, Choi AO, Lam CW: Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One. 2012, doi:10.1371/journal.pone.0029815
32.
go back to reference Chattopadhyay S, Tracy E, Liang P, Robledo O, Rose-John S, Baumann H. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem. 2007;282:3014–26.CrossRefPubMed Chattopadhyay S, Tracy E, Liang P, Robledo O, Rose-John S, Baumann H. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem. 2007;282:3014–26.CrossRefPubMed
33.
go back to reference Ohmatsu H, Sugaya M, Suga H, Morimura S, Miyagaki T, Kai H, et al. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. Acta Derm Venereol. 2012;92:282–3.CrossRefPubMed Ohmatsu H, Sugaya M, Suga H, Morimura S, Miyagaki T, Kai H, et al. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. Acta Derm Venereol. 2012;92:282–3.CrossRefPubMed
34.
go back to reference Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009;113:5942–50.PubMed Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009;113:5942–50.PubMed
35.
go back to reference World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79:373–4. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79:373–4.
36.
go back to reference Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D: Estrogen Deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One. 2012, doi:10.1371/journal.pone.0044552 Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D: Estrogen Deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One. 2012, doi:10.1371/journal.pone.0044552
37.
go back to reference Takayanagi H. Osteoimmunology: shared mechanisms and cross-talk between the immune and bone system. Nat Rev Immunol. 2007;7:292–304.CrossRefPubMed Takayanagi H. Osteoimmunology: shared mechanisms and cross-talk between the immune and bone system. Nat Rev Immunol. 2007;7:292–304.CrossRefPubMed
38.
go back to reference Ghilardi N, Li J, Hongo JA, Yi S, Gurney A, De Sauvage FJ. A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5. J Biol Chem. 2002;10(277):16831–6. Ghilardi N, Li J, Hongo JA, Yi S, Gurney A, De Sauvage FJ. A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5. J Biol Chem. 2002;10(277):16831–6.
39.
go back to reference Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012;91:552–66.CrossRefPubMed Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012;91:552–66.CrossRefPubMed
40.
go back to reference Park K, Park JH, Yang WJ, Lee JJ, Song MJ, Kim HP. Transcriptional activation of the IL31 gene by NFAT and STAT6. J Leukoc Biol. 2012;91:245–57.CrossRefPubMed Park K, Park JH, Yang WJ, Lee JJ, Song MJ, Kim HP. Transcriptional activation of the IL31 gene by NFAT and STAT6. J Leukoc Biol. 2012;91:245–57.CrossRefPubMed
41.
go back to reference O’Brien CA, Gubrij I, Lin SC, Saylorsi LR, Manolagas SC. STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-kB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone. J Biol Chem. 1999;274:19301–8.CrossRefPubMed O’Brien CA, Gubrij I, Lin SC, Saylorsi LR, Manolagas SC. STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-kB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone. J Biol Chem. 1999;274:19301–8.CrossRefPubMed
42.
go back to reference Lencel P, Magne D. Inflammaging: the driving force in osteoporosis? Med Hypotheses. 2011;76:317–21.CrossRefPubMed Lencel P, Magne D. Inflammaging: the driving force in osteoporosis? Med Hypotheses. 2011;76:317–21.CrossRefPubMed
43.
go back to reference Cornelissen C, Brans R, Czaja K, Skazik C, Marquardt Y, Zwadlo-Klarwasser G, et al. Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells. Br J Dermatol. 2011;165:966–75.CrossRefPubMed Cornelissen C, Brans R, Czaja K, Skazik C, Marquardt Y, Zwadlo-Klarwasser G, et al. Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells. Br J Dermatol. 2011;165:966–75.CrossRefPubMed
44.
go back to reference De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579:2035–9.CrossRefPubMed De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579:2035–9.CrossRefPubMed
45.
go back to reference Perrigoue JG, Li J, Zaph C, Goldschmidt M, Scott P, de Sauvage FJ, et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med. 2007;204:481–7.PubMedCentralCrossRefPubMed Perrigoue JG, Li J, Zaph C, Goldschmidt M, Scott P, de Sauvage FJ, et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med. 2007;204:481–7.PubMedCentralCrossRefPubMed
Metadata
Title
Increased levels of interleukin 31 (IL-31) in osteoporosis
Authors
Lia Ginaldi
Massimo De Martinis
Fedra Ciccarelli
Salvatore Saitta
Selene Imbesi
Carmen Mannucci
Sebastiano Gangemi
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2015
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-015-0125-9

Other articles of this Issue 1/2015

BMC Immunology 1/2015 Go to the issue